COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06CXL
|
|||
Drug Name |
Anakinra
|
|||
Synonyms |
Antril
|
|||
Drug Type |
Protein/peptide drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 3 | [1] | |
Other Indication | Rheumatoid arthritis | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN interleukin-1 receptor 1 (IL1R1) | Target Info | Antagonist | [3] |
Anakinra, an interleukin-1 type I receptor antagonist, may reduce systemic inflammation in COVID-19 through blocking activity of the proinflammatory cytokines IL-1. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04364009) Anakinra for COVID-19 Respiratory Symptoms. U.S. National Institutes of Health. | |||
2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 103950. | |||
3 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.